China Approves JandJ Psoriasis Pill
China has approved Johnson and Johnsons oral pill Icotyde for plaque psoriasis. The drug aims to compete with injectable treatments in a major pharmaceutical market.
Insights:
Johnson & Johnson secured regulatory approval in China for Icotyde, an oral psoriasis pill aimed at capturing market share from established injectable treatments. The Thursday morning approval intensifies competition in the world's second-largest pharmaceutical market. The condition affects more than 8.4 million patients nationwide.
